Emerging drug combinations to optimize renovascular protection and blood pressure goals

References

• ManciaGDe BackerGDominiczakA2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens20072561105118717563527
   PubMed Web of Science ®Google Scholar
• Martínez-CastelaoAGórrizJLPortolésJMBaseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort studyBMC Nephrol2011125321970625
   PubMed Web of Science ®Google Scholar
• BuckalewVMJrBergRLWangSRPorushJGRauchSSchulmanGPrevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study GroupAm J Kidney Dis19962868118218957032
   PubMed Web of Science ®Google Scholar
• DeedwaniaPCHypertension and diabetes: new therapeutic optionsArch Intern Med2000160111585159410847251
   PubMedGoogle Scholar
• BarriosVEscobarCDiabetes and hypertension: what is new?Minerva Cardioangiol200957670572219942843
   PubMedGoogle Scholar
• BarriosVEscobarCEcharriRde AlvaroFNew therapeutic progress in cardiorenal protection of the hypertensive patient with a focus on olmesartanVolpeMHot Topics in Hypertension2Modena, ItalyFB Communication2009issue 8124
   Google Scholar
• GrahamIAtarDBorch-JohnsenKEuropean guidelines on cardiovascular disease prevention in clinical practice: executive summary; Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)Eur Heart J200728192375241417726041
   PubMed Web of Science ®Google Scholar
• SchiffrinELLipmanMLMannJFChronic kidney disease: effects on the cardiovascular systemCirculation20071161859717606856
   PubMed Web of Science ®Google Scholar
• HerzogCAMaJZCollinsAJPoor long-term survival after acute myocardial infarction among patients on long-term dialysisN Engl J Med1998339127998059738087
   PubMed Web of Science ®Google Scholar
• BerlTHenrichWKidney–heart interactions: epidemiology, pathogenesis, and treatmentClin J Am Soc Nephrol20061181817699186
   PubMed Web of Science ®Google Scholar
• García-DonaireJARuilopeLMCardiovascular and renal links along the cardiorenal continuumInt J Nephrol2011201197578221603119
   PubMedGoogle Scholar
• MannJFGersteinHCPogueJBoschJYusufSRenal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trialAnn Intern Med2001134862963611304102
   PubMed Web of Science ®Google Scholar
• RuilopeKMSalvettiAJamersonKRenal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) studyJ Am Soc Nephrol200112221822511158211
   PubMed Web of Science ®Google Scholar
• TuckerBFabbianFGilesMThuraisinghamRCRaineAEBakerLRLeft ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failureNephrol Dial Transplant19971247247289141001
   PubMed Web of Science ®Google Scholar
• BarriosVEscobarCMurgaNClinical profile and management of hypertensive patients with chronic ischemic heart disease and renal dysfunction attended by cardiologists in daily clinical practiceJ Hypertens200826112230223518854765
   PubMed Web of Science ®Google Scholar
• HillegeHLFidlerVDiercksGFUrinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general populationCirculation2002106141777178212356629
   PubMed Web of Science ®Google Scholar
• RomundstadSHolmenJKvenildKHallanHEllekjærHMicroalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study; the Nord-Trøndelag Health Study (HUNT), NorwayAm J Kidney Dis200342346647312955674
   PubMed Web of Science ®Google Scholar
• WachtellKIbsenHOlsenMHAlbuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE studyAnn Intern Med20031391190190614644892
   PubMed Web of Science ®Google Scholar
• SarafidisPABakrisGLMicroalbuminuria and chronic kidney disease as risk factors for cardiovascular diseaseNephrol Dial Transplant20062192366237416782993
   PubMed Web of Science ®Google Scholar
• HunsickerLGAdlerSCaggiulaAPredictors of the progression of renal disease in the Modification of Diet in Renal Disease studyKidney Int1997516190819199186882
   PubMed Web of Science ®Google Scholar
• MoralesEValeroMALeónMHernándezEPragaMBeneficial effects of weight loss in overweight patients with chronic proteinuric nephropathiesAm J Kidney Dis200341231932712552492
   PubMed Web of Science ®Google Scholar
• HsuCYMcCullochCEDarbinianJGoASIribarrenCElevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney diseaseArch Intern Med2005165892392815851645
   PubMedGoogle Scholar
• KlagMJWheltonPKRandallBLBlood pressure and end-stage renal disease in menN Engl J Med1996334113187494564
   PubMed Web of Science ®Google Scholar
• ReynoldsKGuDMuntnerPA population-based, prospective study of blood pressure and risk for end-stage renal disease in ChinaJ Am Soc Nephrol20071861928193517475822
   PubMed Web of Science ®Google Scholar
• BakrisGLWilliamsMDworkinLPreserving renal function in adults with hypertension and diabetes: a consensus approachAm J Kidney Dis200036364666110977801
   PubMed Web of Science ®Google Scholar
• JafarTHStarkPCSchmidCHProgression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysisAnn Intern Med2003139424425212965979
   PubMed Web of Science ®Google Scholar
• ManciaGLaurentSAgabiti-RoseiEReappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force documentJ Hypertens200927112121215819838131
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceType 2 diabetes: the management of type 2 diabetesLondonNICE2009 Available from: http://www.nice.org.uk/guidance/CG87
   Google Scholar
• HackamDGKhanNAHemmelgarnBRThe 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2Therapy Can J Cardiol2010265249258
   Web of Science ®Google Scholar
• UpadhyayAEarleyAHaynesSMUhligKSystematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifierAnn Intern Med2011154854154821403055
   PubMed Web of Science ®Google Scholar
• BarriosVBanegasJRRuilopeLMRodicioJLEvolution of blood pressure control in SpainJ Hypertens20072591975197717762665
   PubMed Web of Science ®Google Scholar
• BarriosVEscobarCCalderónABlood pressure and lipid goal attainment in the hypertensive population in the primary care setting in SpainJ Clin Hypertens (Greenwich)20079532432917485967
   PubMedGoogle Scholar
• EscobarCBarriosVCombined therapy in the treatment of hypertensionFundam Clin Pharmacol20102413819682088
   PubMed Web of Science ®Google Scholar
• VolpeMAngiotensin II: an amplifier of cardiovascular riskCurr Hypertens Rep20046424724815257857
   PubMed Web of Science ®Google Scholar
• SchmiederRERuilopeLMBarnettAHRenal protection with angiotensin receptor blockers: where do we standJ Nephrol201124556958021404225
   PubMed Web of Science ®Google Scholar
• BrewsterUCPerazellaMAThe renin-angiotensin-aldosterone system and the kidney: effects on kidney diseaseAm J Med2004116426327214969655
   PubMed Web of Science ®Google Scholar
• FliserDPerspectives in renal disease progression: the endothelium as a treatment target in chronic kidney diseaseJ Nephrol201023436937620349425
   PubMed Web of Science ®Google Scholar
• CampbellDJWoodwardMChalmersJPPrediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular diseaseCirculation2005112111011615983245
   PubMed Web of Science ®Google Scholar
• SchmiederREHilgersKFSchlaichMPSchmidtBMRenin-angiotensin system and cardiovascular riskLancet200736995681208121917416265
   PubMed Web of Science ®Google Scholar
• ParvingHHPerssonFLewisJBLewisEJHollenbergNKAVOID Study InvestigatorsAliskiren combined with losartan in type 2 diabetes and nephropathyN Engl J Med2008358232433244618525041
   PubMed Web of Science ®Google Scholar
• RuggenentiPFassiAIlievaAPPreventing microalbuminuria in type 2 diabetesN Engl J Med2004351191941195115516697
   PubMed Web of Science ®Google Scholar
• HallerHItoSIzzoJLJrOlmesartan for the delay or prevention of microalbuminuria in type 2 diabetesN Engl J Med20113641090791721388309
   PubMed Web of Science ®Google Scholar
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudyHeart Outcomes Prevention Evaluation Study InvestigatorsLancet2000355920025325910675071
   PubMed Web of Science ®Google Scholar
• ParvingHHLehnertHBröchner-MortensenJThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med20013451287087811565519
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med20013451285186011565517
   PubMed Web of Science ®Google Scholar
• ImaiEChanJCItoSEffects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled studyDiabetologia201154122978298621993710
   PubMed Web of Science ®Google Scholar
• BarriosVEscobarCAliskiren in the management of hypertensionAm J Cardiovasc Drugs201010634935821090828
   PubMed Web of Science ®Google Scholar
• AsselbergsFWDiercksGFHillegeHLEffects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuriaCirculation2004110182809281615492322
   PubMed Web of Science ®Google Scholar
• Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathythe GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)Lancet19973499069185718639217756
   PubMed Web of Science ®Google Scholar
• HouFFXieDZhangXRenoprotection of Optimal Antiproteinuric Doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiencyJ Am Soc Nephrol20071861889189817494885
   PubMed Web of Science ®Google Scholar
• ONTARGET InvestigatorsYusufSTeoKKTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• MannJFSchmiederREMcQueenMRenal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trialLancet2008372963854755318707986
   PubMed Web of Science ®Google Scholar
• ReboldiGGentileGAngeliFVerdecchiaPChoice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trialsVasc Health Risk Manag20095141142719475778
   PubMedGoogle Scholar
• WheltonPKBarzilayJCushmanWCClinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Arch Intern Med2005165121401140915983290
   PubMedGoogle Scholar
• PalmerBFRenal dysfunction complicating the treatment of hypertensionN Engl J Med2002347161256126112393824
   PubMed Web of Science ®Google Scholar
• AbeMOkadaKMaruyamaTMatsumotoKRenoprotect and blood pressure lowering effect of low-dose hydrochlorothiazide added to intensive renin-angiotensin inhibition in hypertensive patients with chronic kidney diseaseInt J Clin Pharmacol Ther200947852553219640361
   PubMed Web of Science ®Google Scholar
• AbeMOkadaKMaruyamaTMatsumotoKAntiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney diseasePharmacotherapy20092991061107219698011
   PubMed Web of Science ®Google Scholar
• AbeMOkadaKMaruyamaTMatsumotoSMatsumotoKBlood pressure-lowering and antiproteinuric effect of switching from high-dose angiotensin receptor blockers to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney diseaseInt J Clin Pharmacol Ther201048320621320197015
   PubMed Web of Science ®Google Scholar
• MogensenCEVibertiGHalimiSEffect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIERHypertension20034151063107112654706
   PubMed Web of Science ®Google Scholar
• PatelAADVANCE Collaborative GroupMacMahonSEffects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialLancet2007370959082984017765963
   PubMed Web of Science ®Google Scholar
• HeerspinkHJTherapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathwayAdv Chronic Kidney Dis201118429029921782135
   PubMed Web of Science ®Google Scholar
• GojanovicBFeihlFLiaudetLWaeberBConcomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertensionJ Renin Angiotensin Aldosterone Syst2008911918404602
   PubMed Web of Science ®Google Scholar
• MesserliFHVasodilatory edema: a common side effect of antihypertensive therapyCurr Cardiol Rep20024647948212379167
   PubMedGoogle Scholar
• GalceranJPlanaJFelipAPouGVilaJSobrinoJManidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockersExpert Rev Cardiovasc Ther20108675175720528630
   PubMedGoogle Scholar
• Martinez-MartinFJSaiz-SatjesMAdd-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA studyExpert Rev Cardiovasc Ther20086101347135519018688
   PubMedGoogle Scholar
• HayashiKWakinoSSuganoNOzawaYHommaKSarutaTCa2+ channel subtypes and pharmacology in the kidneyCirc Res2007100334235317307972
   PubMed Web of Science ®Google Scholar
• WinerNFolkerAMurphyJAEffect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetesPrev Cardiol200582879215860983
   PubMedGoogle Scholar
• FogariRPretiPZoppiAEffects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patientsAm J Hypertens200215121042104912460699
   PubMed Web of Science ®Google Scholar
• FujitaTAndoKNishimuraHAntiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal diseaseKidney Int200772121543154917943080
   PubMed Web of Science ®Google Scholar
• EganCGPontremoliRRole of the fixed-dose combination lercanidipine-enalapril in renal protectionJ Nephrol201124442843721279953
   PubMed Web of Science ®Google Scholar
• BarriosVNavarroAEsterasAAntihypertensive efficacy and tolerability of lercanidipine in daily clinical practice: the ELYPSE study; Eficacia de Lercanidipino y su Perfil de SeguridadBlood Press20021129510012035878
   PubMed Web of Science ®Google Scholar
• BarriosVEscobarCde la FigueraMTolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE studyCardiovasc Ther20082612918466416
   PubMed Web of Science ®Google Scholar
• BarriosVEscobarCNavarroALercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA studyInt J Clin Pract200660111364137017073834
   PubMed Web of Science ®Google Scholar
• Dalla VestraMPozzaGMoscaAEffect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (diabete ipertensione, albuminuria, lercanidipina)Diabetes Nutr Metab200417525926616295047
   PubMedGoogle Scholar
• RoblesNROconJGomezCFLercanidipine in patients with chronic renal failure: the ZAFRA studyRen Fail2005271738015717638
   PubMed Web of Science ®Google Scholar
• RoblesNRRomeroBde VinuesaEGSánchez-CasadoECuberoJJTreatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugsRen Fail201032219219720199181
   PubMed Web of Science ®Google Scholar
• BakrisGLSarafidisPAWeirMRRenal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trialLancet201037597211173118120170948
   PubMed Web of Science ®Google Scholar
• BarriosVEscobarCAntihypertensive and organ-protective effects of benazeprilExpert Rev Cardiovasc Ther20108121653167121108548
   PubMedGoogle Scholar
• MogensenCENeldamSTikkanenIRandomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) studyBMJ200032172741440144411110735
   PubMed Web of Science ®Google Scholar
• AndersenNHPoulsenPLKnudsenSTLong-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II studyDiabetes Care200528227327715677778
   PubMed Web of Science ®Google Scholar
• TütüncüNBGürlekAGedikOEfficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective studyActa Diabetol200138415716111855793
   PubMed Web of Science ®Google Scholar
• JenningsDLKalusJSColemanCIManierskiCYeeJCombination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysisDiabet Med200724548649317367311
   PubMed Web of Science ®Google Scholar
• MaioneANavaneethanSDGrazianoGAngiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trialsNephrol Dial Transplant20112692827284721372254
   PubMed Web of Science ®Google Scholar